Reference | </br>1:Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia. Rydholm H, von Corswant C, Denison H, Jensen JM, Lehmann A, Ruth M, Söderlind E, Aurell-Holmberg A.Clin Ther. 2016 Apr;38(4):946-60. doi: 10.1016/j.clinthera.2016.02.012. Review. PMID: 26947796 </br>2:Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. Miner PB Jr, Silberg DG, Ruth M, Miller F, Pandolfino J.BMC Gastroenterol. 2014 Nov 18;14:188. doi: 10.1186/1471-230X-14-188. PMID: 25407279 Free PMC Article</br>3:Systemic exposure to the metabolites of lesogaberan in humans and animals: a case study of metabolites in safety testing. Holmberg AA, Ekdahl A, Weidolf L.Drug Metab Dispos. 2014 Jun;42(6):1016-21. doi: 10.1124/dmd.113.056614. Epub 2014 Mar 21. PMID: 24658456 Free Article</br>4:Development of analytical methods for the quantification of metabolites of lesogaberan in a MIST investigation. Dunér K, Bottner P, Norlén AK.Biomed Chromatogr. 2014 Mar;28(3):362-8. doi: 10.1002/bmc.3029. Epub 2013 Sep 5. PMID: 24037996 </br>5:Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography. Ekdahl A, Aurell-Holmberg A, Castagnoli N Jr.Xenobiotica. 2013 May;43(5):461-7. doi: 10.3109/00498254.2012.725486. Epub 2012 Oct 3. PMID: 23030741 </br>6:Antitussive effects of the peripherally restricted GABAB receptor agonist lesogaberan in guinea pigs: comparison to baclofen and other GABAB receptor-selective agonists. Canning BJ, Mori N, Lehmann A.Cough. 2012 Oct 1;8(1):7. doi: 10.1186/1745-9974-8-7. PMID: 23025757 Free PMC Article</br>7:Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Shaheen NJ, Denison H, Björck K, Karlsson M, Silberg DG.Gut. 2013 Sep;62(9):1248-55. doi: 10.1136/gutjnl-2012-302737. Epub 2012 Jun 23. PMID: 22730470 </br>8:Effect of food on the bioavailability of lesogaberan given as an oral solution or as modified-release capsules in healthy male volunteers. Fransson B, Silberg DG, Niazi M, Miller F, Ruth M, Holmberg AA.Int J Clin Pharmacol Ther. 2012 Apr;50(4):307-14. PMID: 22456303 </br>9:Translational gastrointestinal pharmacology in the 21st century: /’the lesogaberan story/’. Boeckxstaens GE, Denison H, Jensen JM, Lehmann A, Ruth M.Curr Opin Pharmacol. 2011 Dec;11(6):630-3. doi: 10.1016/j.coph.2011.10.011. Epub 2011 Oct 27. Review. PMID: 22036168 </br>10:Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor. Niazi M, Skrtic S, Ruth M, Holmberg AA.Drugs R D. 2011;11(1):77-83. doi: 10.2165/11590310-000000000-00000. PMID: 21410297 Free PMC Article
|